CDK7 and acute lymphoblastic leukemia: A previous study showed that the SE regulator CDK7 inhibitor THZ1 caused significant tumor regression in MYCN-amplified neuroblastoma cells and affected RUNX1 transcription in Jurkat T-ALL cells [125].